Jiaxin Wu - Concepedia

Author

Jiaxin Wu

University of Science and Technology of China ORCID

Also Known As

J Wu, J. Wu, Jiaxin WU, Jiaxin Wu, Jia‑Xin Wu, Jingzhi Wu, Wu, Jiaxin

Publications

960

Citations

H-Index

Concepts

All Affiliations

University of Science and Technology of China Hefei Institutes of Physical Science Chinese Academy of Sciences High Magnetic Field Laboratory The University of Texas Health Science Center at Houston

About

Jiaxin Wu is an author at University of Science and Technology of China specializing in medicine, cell biology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	329
2	Natural Sciences	3	3	95
3	Biochemistry	2	2	78
4	Biomolecular Engineering	2	2	71
5	Health Sciences	1	1	15

Jiaxin Wu

Publications

837

Citations

H-Index

Page 1

	Year	Citations
Surface Iron Species in Palladium–Iron Intermetallic Nanocrystals that Promote and Stabilize CO<sub>2</sub> Methanation Laihao Luo, Menglin Wang, Yi Cui, Angewandte Chemie International Edition	2020	79
Berberine Damages the Cell Surface of Methicillin-Resistant Staphylococcus aureus Xiujuan Zhang, Xiaoying Sun, Jiaxin Wu, Frontiers in Microbiology	2020	63
Discovery of N -(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC Yongfei Chen, Jiaxin Wu, Aoli Wang, European Journal of Medicinal Chemistry Drug TargetMedicineRational Drug DesignPharmacotherapyAnti-cancer Agent	2017	58
Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor Beilei Wang, Jiaxin Wu, Yun Wu, European Journal of Medicinal Chemistry Medicinal ChemistryBiochemistryMedicineNatural SciencesReceptor Tyrosine Kinase	2018	50
Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells Hong Wu, Aoli Wang, Wei Zhang, Oncotarget Novel TherapyMedicineReceptor Tyrosine KinaseImmunologyPharmacology	2015	46
Solution Structure of the Second Extracellular Loop of Human Thromboxane A<sub>2</sub> Receptor Ke‐He Ruan, Shui‐Ping So, Jiaxin Wu, Biochemistry	2000	44
Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)phenyl)-3-(5-(<i>tert</i>-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML Aoli Wang, Xixiang Li, Cheng Chen, Journal of Medicinal Chemistry	2017	37
Physical and Functional Antagonism between Tumor Suppressor Protein p53 and Fortilin, an Anti-apoptotic Protein Yanjie Chen, Takayuki Fujita, Di Zhang, Journal of Biological Chemistry	2011	36
Solution structure and topology of the N-terminal membrane anchor domain of a microsomal cytochrome P450: prostaglandin I2 synthase Ke‐He Ruan, Shui‐Ping So, Weida Zheng, Biochemical Journal	2002	34
Discovery of (<i>R</i>)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode Aoli Wang, Xixiang Li, Hong Wu, Journal of Medicinal Chemistry Inhibitor Compound 19Molecular BiologyChemical BiologyPharmaceutical ChemistryTumor Biology	2017	32

Page 1